|Day Low/High||40.52 / 40.70|
|52 Wk Low/High||36.81 / 44.50|
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
Data also Shows Men Consider Sexual Health to be an Important Priority
Wall Street runs at two speeds as a rally in financials sent the Dow Jones Industrial Average to close at records, while a selloff in tech sank the Nasdaq.
Wall Street remains divided on Thursday as investors try to gauge the types of policies president-elect Donald Trump could enact.
MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Wall Street runs at two speeds on Thursday with the Dow Jones Industrial Average setting a record high and the S&P 500 and Nasdaq slipping.
Stock futures move higher on Thursday with the Dow Jones Industrial Average set to open at a high.
As we all know, the stock market and the economy abhor uncertainty.
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.
Economic data in France disappoints; Germany and U.K. beat expectations.
The pharmaceutical company reported better-than-expected results on Friday morning. Grab its ADRs now.
Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.
Analysts are expecting to see a year-over-year decline in earnings and revenue when Sanofi (SNY) posts 2016 third-quarter results before Friday's market open.
U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety
- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -
The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.
Gainers include ArcelorMittal, Lafargeholcim, Nokia, Maersk
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.